The answer, first
The answer, first. Tesamorelin, CJC-1295 with ipamorelin, and MOTS-c are not three versions of the same drug. The community record separates them cleanly: tesamorelin for a smaller waist without scale movement, CJC with ipamorelin for recovery, strength and fullness, MOTS-c for training energy during a deficit.
Every one of those reports is consistent with the clinical record. None of them is a muscle-gain claim, and that is the finding. Growth-hormone-axis compounds reliably move a body-composition scan. When a trial measured what the extra mass actually was, it was noncontractile protein and water, and the strength gains matched placebo7.
Only tesamorelin holds a randomized human trial with a body-composition endpoint, that trial ran in adults with HIV-associated lipodystrophy, and its label says explicitly that it is not indicated for weight management1,2.
Ipamorelin's only published randomized trial was for gut motility after surgery, and it did not separate from placebo6. MOTS-c has no completed human outcome trial at all9.
The honest summary is narrow and useful: these compounds do something, the something is smaller than the marketing, and the number on your scan is the least trustworthy part of it.
- Fat-free mass and muscle are not the same measurement. In a randomized trial of resistance training with growth hormone or placebo, fat-free mass and total body water rose more on GH, while muscle protein synthesis, creatinine excretion and training-specific strength gains were the same in both groups. The authors attributed the difference to noncontractile protein and fluid retention7.
- The community record already says this, in its own words. Across the sweep, the recurring language is fullness, retention, recovery, definition and better sessions. Large muscle-gain claims are uncommon, disputed, or measured on a consumer body scanner.
- Tesamorelin has the only randomized body-composition endpoint. In 412 adults with HIV and abdominal fat accumulation, CT-measured visceral adipose tissue fell 15.2% against a 5.0% rise on placebo over 26 weeks, and IGF-I rose 81.0%1. Stopping treatment reversed the visceral-fat change3.
- Visible belly fat and visceral fat are different compartments. The trial endpoint was measured by CT. A mirror, a waistband and a consumer scale cannot see the compartment the drug was approved to move.
- Ipamorelin has been in a randomized human trial. It was not about muscle. A phase 2 in 114 bowel-resection patients tested it for postoperative ileus and found no significant difference from placebo on the key or secondary efficacy analyses6. That is a null on a gut endpoint, not a verdict on body composition, and nobody has run the body-composition trial.
- MOTS-c is a mouse result with a human trial still recruiting. The founding paper identified a sixteen-amino-acid peptide from mitochondrial 12S rRNA that activates AMPK and prevented diet-induced obesity in mice8. The first registered phase 2a in humans has posted no results9.
- A secretagogue can raise lean body mass and worsen your glucose at the same time. In 395 older adults, an oral GH secretagogue raised lean mass 1.4 kg against 0.3 kg on placebo and improved two physical-function measures, alongside fatigue, insomnia and small rises in fasting glucose, glycosylated haemoglobin and insulin-resistance indices. The study was stopped early10.
- No efficacy percentages were calculated from community reports. Thread volume measures discussion, not success.
The ranked field
The same A to E ladder this site applies to everything else. A grade describes the strength of the human record for the specific claim in the row, not the plausibility of the mechanism and not the enthusiasm of the market.
Why the scan moves
This is the section that reconciles the two records, and it rests on one trial from 1995 that almost nobody selling these compounds cites.
Twenty-three healthy sedentary men, average age 67, ran a sixteen-week progressive resistance programme at 75 to 90 percent of maximum strength, four days a week.
They were randomized to growth hormone or placebo. Fat-free mass increased more in the GH group. So did total body water. Whole-body protein synthesis and breakdown both rose.
Then the measurements that matter came back. Muscle protein synthesis in the vastus lateralis: the same in both groups. Urinary creatinine excretion, a marker of muscle mass: the same.
Training-specific isotonic and isokinetic strength: the same. The authors wrote that the greater fat-free-mass increase with GH "may have been due to an increase in noncontractile protein and fluid retention"7.
Resistance training worked. Adding growth hormone to it did not add muscle. It added mass that a scan counts as lean and a fibre does not.
Fat-free mass went up. Muscle protein synthesis did not.
That result is thirty years old and it explains the modern community record precisely. Users on CJC with ipamorelin do not usually report getting bigger. They report fullness, retention, better sessions, less soreness and a fuller look under the same conditions.
Fullness under a scan is exactly what noncontractile protein and fluid produce. The most calibrated post in the entire sweep put it in one line: useful for retention and fullness on a cut. The effect on actual muscle gain was described as basically non-existent.
The counterweight is real and belongs here. In 395 older adults with mild functional limitation, an oral GH secretagogue produced a sustained IGF-I rise. Lean body mass rose 1.4 kg against 0.3 kg on placebo.
Tandem walk improved measurably at six months and stair climb at twelve. That is a functional gain, not just a number10. Three things sit beside it.
Total body weight rose by the same 1.4 kg, which is what fluid does. Fasting glucose, glycosylated haemoglobin and insulin-resistance indices all rose. And the trial was stopped early against predetermined criteria.
The compound was capromorelin, taken orally, in adults over 65 with functional limitation. It is not ipamorelin, and the population is not a lifter in a deficit.
So the honest reading is neither dismissal nor endorsement. GH-axis compounds move body-composition measurements. Whether the moved measurement is contractile muscle is the open question, and the one trial that looked directly at that question found it was not.
reader skillsLooking at any of these compounds regardless? Read the certificate before the claim.The five measures a real COA carries, what most certificates skip, and how to verify one with the lab — in five minutes.→
Tesamorelin and the waist
Tesamorelin has the cleanest evidence on this page and the narrowest licence.
In 412 adults with HIV and abdominal fat accumulation, 2 mg daily for 26 weeks reduced CT-measured visceral adipose tissue by 15.2% while the placebo group gained 5.0%. Triglycerides fell 50 mg per decilitre, the total-to-HDL cholesterol ratio improved, and IGF-I rose 81.0%1.
A second phase 3 in 404 adults confirmed the visceral-fat and waist effects, and showed that the improvement reversed when treatment stopped3. The FDA label is explicit that the drug reduces excess abdominal fat in adults with HIV and lipodystrophy, and that it is not indicated for weight management2.
The community sweep produced a signal that matches the pharmacology more closely than a generic weight-loss story would. The repeated pattern is a flat scale with a changed midsection: a tighter core, a smaller-feeling waist, better definition, and no movement in weight.
One report on r/BodyHackGuide in May 2026 described a noticeable change in body composition and a tighter midsection at eight weeks, with the scale unmoved. The same post disclosed calorie restriction, five training days a week, daily cardio and a high step count.
A report on r/PeptidePathways the same month described no physical change and no scale result after roughly two months, alongside tracked calories, protein and gym attendance.
The measurement gap is the problem, and it runs in the direction people do not expect. Visible lower-belly fat is mostly subcutaneous. Visceral fat sits around the organs and needs imaging or a validated surrogate to see.
The trial moved the compartment you cannot see in a mirror. The community is grading the compartment you can. Those are not the same claim, and a positive report about one is not evidence for the other.
CJC plus ipamorelin
This is the most-discussed pairing in the sweep, at 423 body-composition thread pairs, and the least resolvable.
Start with the label problem. On the forums, CJC-1295 refers to at least three different things. Those are the long-acting analogue with a drug affinity complex, a no-DAC product usually described as modified GRF, and blends whose composition is not stated.
A 2026 clinical review of this exact compound class names the same ambiguity. It catalogues what turns up in practice: fluid-retention syndromes, dysglycaemia, prolactin and cortisol elevations, myalgia and arthralgia, and injection-site reactions11.
Aggregating community reports across three different molecules is not possible, and that is before product identity enters the picture.
What the human record does contain: CJC-1295 produces prolonged GH and IGF-I elevation in healthy adults, established in a randomized double-blind study whose endpoints were hormone concentrations and pharmacokinetics5. It does not contain a single trial of the combination against a body-composition endpoint.
Ipamorelin's record is more interesting than its absence suggests. It has been through a randomized, placebo-controlled human trial: 114 bowel-resection patients, given ipamorelin twice daily for up to seven days, testing recovery of gut motility after surgery.
It was well tolerated. Median time to first tolerated meal was 25.3 hours against 32.6 on placebo, and the difference did not reach significance.
The published conclusion states there were no significant differences on the key and secondary efficacy analyses6. That result says nothing directly about muscle. What it does say is that when this molecule was put in front of a placebo arm with a defined endpoint, it did not separate.
The community reports are correspondingly modest and, read carefully, internally consistent. Better sleep and recovery come first. Stronger sessions, fuller muscles, more definition and better retention during a cut follow.
A February 2026 log on r/Biohackers described stronger bench and squat work, less soreness, fuller muscles and slight midsection leanness at eight weeks, as a single uncontrolled training record.
An October 2025 comment on r/BodyHackGuide reported no real change at five weeks. A November 2025 report describing a leaner, more toned look at six weeks also disclosed regular extended fasting and a concurrent peptide. The people reporting are frequently more careful than the people selling.
MOTS-c and energy
MOTS-c earns its best community feedback when the question changes from whether it built muscle to whether it helped someone train while cutting. Energy, endurance, workout output and reduced fatigue recur across 231 body-composition thread pairs.
Direct fat-loss claims exist and are almost always accompanied by a GLP-1, a calorie deficit, resistance training, or another mitochondrial compound.
Even the enthusiasts calibrate. A September 2025 comment on r/Peptidesource landed on the distinction the whole file supports: not much for fat loss, useful for energy in a deficit. A null report in the same thread described zero difference.
A June 2020 post on r/Peptides reported midsection and love-handle changes and then noted the estimate came from a consumer scale the author called unreliable. An August 2026 cyclist's report described abundant energy at any intensity, then listed weight loss, testosterone, training and recovery as competing explanations for it.
The human file is empty rather than negative. MOTS-c was identified in 2015 as a sixteen-amino-acid peptide encoded within mitochondrial 12S rRNA, targeting skeletal muscle, inhibiting the folate cycle and its tethered purine biosynthesis, and activating AMPK. In mice it prevented age-dependent and high-fat-diet-induced insulin resistance and diet-induced obesity8.
The first registered phase 2a in humans is recruiting adults with prediabetes and overweight or obesity, measures insulin sensitivity, weight and waist, and has posted no results9.
FDA reviewed MOTS-c at its July 2026 compounding advisory meeting and its current risk page states it has not identified human exposure data from MOTS-c drug products12,13.
An advisory review is not an approval and not an efficacy finding. A recruiting trial is not a result. Grade E is not an insult here. It is a description of a file that has not been written yet.
The sweep
The archive sweep ran on 23 August 2026 across r/Peptidesource, r/Peptides, r/BodyHackGuide, r/Biohackers, r/PeptidePathways and r/PeptideGuide, covering 1 January 2020 to 23 August 202614.
The search strings were the compound names and the common community abbreviations. For each subreddit and query pair the archive returned up to 100 oldest and 100 newest posts. Results were deduplicated by thread and by compound, because 136 outcome-matched threads discussed more than one target.
| Scrape layer | Retrieved record |
|---|---|
| Raw post rows | 3,700 |
| Unique threads | 3,138 |
| Compound-thread pairs | 3,420 |
| Body-composition-matched threads | 795 |
| Body-composition pairs · CJC plus ipamorelin | 423 |
| Body-composition pairs · tesamorelin | 296 |
| Body-composition pairs · MOTS-c | 231 |
| High-signal threads with comments pulled | 68 |
| Comments retrieved | 4,879 |
| Comments matching the outcome vocabulary | 587 |
A heuristic flagged 86 MOTS-c posts, 129 tesamorelin posts and 165 CJC-with-ipamorelin posts as possible first-person outcome reports. Those are review queues, not positive-result counts. A further 125 body-composition pairs carried promotional markers such as affiliate language, vendor discussion or formulaic protocol guides.
The sweep is reproducible and not exhaustive. It excludes deleted, private, inaccessible and unindexed material. The oldest-plus-newest cap is a sample rather than a census, and comment review concentrated on high-engagement threads.
Quotes are reported by platform and month only, without usernames, doses, preparation details or vendor names, and no community report was converted into a success rate.
What the photos cannot show
A transformation post proves a transformation happened. It does not identify the cause.
The strongest-looking posts in this sweep almost all contain the same stack of confounders. That stack is a GLP-1, testosterone or another anabolic, a substantial calorie deficit, high protein intake, frequent resistance training and cardio.
One CJC-with-ipamorelin transformation was challenged in its own comment thread for omitting additional performance-enhancing drugs. A MOTS-c before-and-after included retatrutide, meal preparation, frequent training and DXA data, which is better measurement and no help at all with attribution.
Not one reviewed photo series isolated a single target compound with standardized lighting, pose, diet, training, an assayed product and objective pre-and-post body composition. Photographic evidence on this question stays at grade D, and a better camera does not move it.
What does not count
- Scale weight as a tesamorelin test. The trial endpoint was visceral adipose tissue on CT. Total weight was never the target.
- A flatter-looking stomach as proof of visceral-fat loss. Visible abdominal fat is largely subcutaneous. The two compartments are separate and only one was measured.
- A GH or IGF-1 rise as proof of muscle growth. A biomarker confirms the pathway is active. Yarasheski measured the pathway working and the muscle not growing in the same subjects7.
- A DXA or consumer-scanner lean-mass increase as proof of new muscle. Fluid and glycogen move that reading, and fluid retention is a documented effect of this compound class11.
- A stack transformation as single-compound evidence. Concurrent GLP-1s, androgens, diet and training dominate attribution and cannot be subtracted after the fact.
- Thread volume as an efficacy rate. Positive selection, affiliate amplification, duplicate discussion and the silence of people who quit make that calculation impossible.
- A null report as proof the compound does nothing. It cannot be separated from a misidentified vial, degraded product, poor handling, short observation or unrealistic expectation. The same uncertainty limits every positive report on the page.
What you can control
Nothing on this page can be argued into a better grade. The trials either exist or they do not, and for two of these three compounds they do not. No amount of community volume closes that gap, and neither does a better photograph.
One variable is still open, and it is the only one a reader owns. Whether the vial in your hand contains what the label says is not a question about the literature.
It is a question about a document, and the document can be checked in five minutes before any money moves. A real certificate names the lab, prints an accession number, matches your lot, and reports five measures rather than one. Most certificates in this market do not.
That is the honest order, and it does not depend on which way the evidence eventually falls. Read the certificate, then verify it with the lab that issued it. Treat anything short of that as an unknown rather than a risk you have priced.
The compounds on this page have been in circulation for years without the trials that would settle them. The paperwork is the part that was never out of reach.
FAQ
Which of these three has the best evidence for fat loss?
Tesamorelin, and only for one thing in one population. In adults with HIV-associated lipodystrophy it reduced CT-measured visceral adipose tissue by 15.2% over 26 weeks against a 5.0% rise on placebo1.
Its label states it is not indicated for weight management2. For a healthy adult wanting visible abdominal fat loss, there is no trial, and the community record on that question grades D.
Does CJC-1295 with ipamorelin build muscle?
No trial of the combination against a body-composition endpoint has been published. CJC-1295 raises GH and IGF-I, which is established5. Ipamorelin's one randomized human trial tested gut motility after surgery and did not separate from placebo6.
The community record describes recovery, strength, fullness and retention far more often than new muscle, which is what the GH-and-training trial would predict7.
Why do people say they look fuller but not bigger?
Because that is what the measurement does. In the randomized training trial, growth hormone increased fat-free mass and total body water while muscle protein synthesis, creatinine excretion and strength gains matched placebo.
The authors attributed the extra mass to noncontractile protein and fluid retention7. Fullness is a real observation about a real change. It is not evidence of new contractile tissue.
Is MOTS-c a fat-loss compound?
Not on the human record, because there is not one yet. The founding evidence is a mouse study showing AMPK activation and prevention of diet-induced obesity8.
The first registered human phase 2a has posted no results9. The recurring community report is training energy during a deficit rather than direct fat loss, and that is a training input, not a body-composition outcome.
Can I treat CJC-1295 as one compound?
No. The term covers the long-acting analogue with a drug affinity complex, a no-DAC product commonly described as modified GRF, and undisclosed blends.
A 2026 clinical review of this class names the same ambiguity11. Two people reporting on CJC-1295 may not be reporting on the same molecule, and neither can confirm what was in the vial.
If the evidence is this thin, why is the community record so consistent?
Consistency and accuracy are different properties. A community can converge reliably on a real experience. The language of fullness, recovery and a tighter waist is specific and it recurs. What that community cannot establish is what caused the experience, or how much of it there was.
That is precisely the ceiling this site has documented for aggregated anecdote, and this file sits exactly at it.
What would change these grades?
For tesamorelin, a randomized trial with an imaging endpoint in adults without HIV. For CJC with ipamorelin, any randomized trial of the actual combination with a body-composition endpoint and an assayed product. For MOTS-c, results from the registered phase 2a. Until then the grades describe the file, and the file is thin.
Correction, 24 August 2026. Row 07 originally read "No trial" for tesamorelin and abdominal fat outside HIV. Makimura 2012 is exactly that trial — 60 abdominally obese adults without HIV, randomised, double-blind, 12 months — and it was missed. It does not weaken the finding above. It is the cleanest published statement of it, because the same trial found subcutaneous fat unchanged. The row is regraded B and the reference added.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357:2359-2370. PMID 18057338
- US Food and Drug Administration. Tesamorelin prescribing information, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022505s018lbl.pdf
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension. J Acquir Immune Defic Syndr. 2010;53:311-322. PMID 20101189
- Adrian S, Scherzinger A, Sanyal A, et al. The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. J Frailty Aging. 2019;8:154-159. PMID 31237318
- Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91:799-805. PMID 16352683
- Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29:1527-1534. PMID 25331030
- Yarasheski KE, Zachwieja JJ, Campbell JA, Bier DM. Effect of growth hormone and resistance exercise on muscle growth and strength in older men. Am J Physiol. 1995;268:E268-E276. PMID 7864103
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21:443-454. PMID 25738459
- ClinicalTrials.gov. MOTS-c metabolic study, NCT07505745. https://clinicaltrials.gov/study/NCT07505745
- White HK, Petrie CD, Landschulz W, et al. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009;94:1198-1206. PMID 19174493
- Dominikowski A, Rekos Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating the GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. PMID 42395176
- US Food and Drug Administration. Certain bulk drug substances for use in compounding may present significant safety risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- US Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026. https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- Arctic Shift public Reddit archive, API documentation. https://github.com/ArthurHeitmann/arctic_shift/blob/master/api/README.md
- Glesby MJ, Hanna DB, Hoover DR, et al. Recombinant human growth hormone and rosiglitazone for abdominal fat accumulation in HIV-infected patients with insulin resistance: a randomized, double-blind, placebo-controlled, factorial trial. PLoS One. 2013;8:e61160. PMID 23593417
- Makimura H, Feldpausch MN, Rope AM, et al. Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial. J Clin Endocrinol Metab. 2012. PMID 23015655
Inside Your Peptides is published by the owners of the next lab, a vendor graded elsewhere on this site. We sell nothing here. The report above contains no vendor link — evidence pages carry none by policy — and the sourcing desk that follows it is separate, and disclosed.
This report is for research and educational purposes only. It is not medical advice, and it contains no dosing guidance. Tesamorelin is approved for one population and one indication; the other compounds discussed are not approved for any body-composition use. Community reports are described as community reports throughout and were not converted into success rates. Speak to a qualified clinician before making any decision about your health.